Painful Skin Bumps and HLRCC: Why Skin Leiomyomas Can Be an Early Clue

HLRCC can affect the skin as well as the kidneys. Small, firm bumps that are tender to the touch or sting in the cold can be an early clue. Recognizing them can lead to genetic counseling, testing and kidney surveillance for affected people and at-risk relatives.
What are skin leiomyomas?
HLRCC is an inherited condition caused by a harmful (disease-causing) variant in the FH gene, which makes an enzyme called fumarate hydratase. People with HLRCC tend to develop benign (non-cancerous) growths made of smooth muscle, called leiomyomas, in the skin and, in women, in the uterus. They also have a higher risk of a type of kidney cancer. You can learn the basics in our HLRCC Handbook.
According to MedlinePlus Genetics from the U.S. National Library of Medicine, skin leiomyomas (doctors call them cutaneous leiomyomas):
- Usually appear in a person’s 20s.
- Most arise from tiny muscles around hair follicles, the same muscles that give you goosebumps.
- Look like bumps or nodules on the trunk, arms and legs, and occasionally the face. They may be skin-colored or darker.
- Often increase in size and number over time.
- Can be more sensitive than the surrounding skin to cold or light touch, and may be painful.
Not everyone with HLRCC has them. Some people have only a few, and some have none at all. So clear skin does not rule HLRCC out.
Why one bump is different from many
Single skin leiomyomas can happen in people without HLRCC. Multiple ones are a stronger signal.
A study from the University of California, San Francisco looked at this directly. Researchers studied 22 patients with multiple skin leiomyomas and 25 with a single one. When the tumors were tested, changes in the FH gene were found in 11 of 13 sequenced tumors from people with multiple leiomyomas (85%), compared with 1 of 11 from single leiomyomas (9%). The authors concluded that multiple skin leiomyomas should raise the possibility of HLRCC, and that special lab stains for FH and a marker called 2SC are helpful and should be considered for every newly diagnosed skin leiomyoma.
A reminder from a recent case
A case report published in the American Journal of Dermatopathology in October 2026 describes a 40-year-old woman with many small bumps on both sides of her face that had slowly spread over 15 years. She noticed slight pain when eating spicy food, and her younger sister had similar bumps. A biopsy showed pilar leiomyomas (the hair-follicle type), and staining showed loss of the FH protein, which pointed to HLRCC. The report described no kidney masses on abdominal ultrasound. The authors’ message is one we share: unusual skin bumps can be part of a syndrome and deserve a closer look.
Why an early clue matters
In a 2014 international consensus paper, an expert group including Dr. W. Marston Linehan of the National Cancer Institute estimated lifetime kidney cancer risk in HLRCC at approximately 15 in 100 (about 15%), which means most people with HLRCC don’t get kidney cancer. Because the kidney cancer that does occur can be aggressive, the group recommended careful screening. They advised surveillance, preferably annual abdominal MRI, and consideration of predictive testing for the family’s disease-causing FH variant from ages 8–10, with decisions individualized after discussing potential benefits and drawbacks.
In other words, a dermatologist who recognizes a skin leiomyoma may be the person who helps a family find HLRCC before kidney cancer does.
What you can do
- Mention it. If you have several firm, tender skin bumps, show them to your doctor or a dermatologist, and share any family history of fibroids, skin bumps or kidney cancer.
- Ask about the biopsy. If a bump is removed, it’s reasonable to ask whether the tissue was checked for FH.
- Consider genetic counseling. Our Genetic Testing page explains how testing works, and our FAQ answers common questions.
- Find an expert. Our HLRCC Specialists Map lists centers with HLRCC experience.
Get connected
You’re not alone. Join the HLRCC Foundation Facebook group, read the free HLRCC Handbook, or help us raise awareness by donating. Recognizing the signs can help families seek appropriate care.
Sources
- MedlinePlus Genetics. Hereditary leiomyomatosis and renal cell cancer. U.S. National Library of Medicine.
- Buelow B, Cohen J, Nagymanyoki Z, et al. Immunohistochemistry for 2-succinocysteine (2SC) and fumarate hydratase (FH) in cutaneous leiomyomas may aid in identification of patients with HLRCC. Am J Surg Pathol. 2016;40(7):982–988. doi:10.1097/PAS.0000000000000626. PubMed: 26945337.
- Almadan N, Althubaiti R, Almotairi A, et al. Dissecting a diagnostic enigma, multiple bilateral facial nodules in a middle aged woman. Am J Dermatopathol. 2026;48(10):810–814. doi:10.1097/DAD.0000000000003399. PubMed: 42566391.
- Menko FH, Maher ER, Schmidt LS, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer. 2014;13(4):637–644. doi:10.1007/s10689-014-9735-2. Free full text (PMC4574691).
- Kamihara J, Schultz KA, Rana HQ. FH Tumor Predisposition Syndrome. GeneReviews®. University of Washington, Seattle; updated 2025. NBK1252 (background reading).
- National Cancer Institute. Hereditary Leiomyomatosis and Renal Cell Cancer (PDQ®)–Health Professional Version. PDQ Cancer Genetics Editorial Board; updated November 6, 2024.